Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s):  ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


TSX:ATE - Post by User

Post by MrMugsyon Sep 10, 2022 9:07am
284 Views
Post# 34954027

AGM ...

AGM ...15% of the shares voted - tells me mostly insiders with 1M-2M outside shares voted. (max).
Roughly 8M of the 52M outstanding shares voted.

---------------

CITA could close soon.
Commercial study - have now and will review next week - share info in the next 2-3 weeks.
Antiviral is early stage - look beyond COVID to respiratory diseases in the future.
Phase 2 to start around September 28th and top-line expected before Christmas.
FDA Fast-track is a "one shot" deal so they need to get it right - confidence in the data to guide decision of when to apply

---------------

For those of you that want to hold me to the above timing - go to Hades.

For the rest of you ... enjoy !!!

Hahaha !
<< Previous
Bullboard Posts
Next >>